Xinguang completes 100 million yuan angel round led by Qiming Venture Partners

Dedicated to providing core optical interconnect products and next-generation full-stack optical interconnect solutions for global AI computing clusters, with the aim of becoming the defining force in optical interconnect technology for the world's AI infrastructure.

Recently, Shanghai Xinguangjie Intelligent Technology Co., Ltd. (hereinafter referred to as "Xinguang"), a Chinese optical interconnect startup, announced that it has successfully completed its angel funding round. This round was led exclusively by Qiming Venture Partners, a top-tier venture capital firm, with total financing reaching RMB 100 million. The funding will provide solid financial support for the company's core technology R&D, product iteration, and team building. Going forward, Xinguang will concentrate its core resources on tackling key industry technologies, accelerating the commercialization of NPO products, conducting frontier CPO technology pre-research and iteration, advancing product customer validation and scenario adaptation, while simultaneously recruiting top-tier talent in the field to strengthen the company's core advantages and technical moat.

Xinguang was launched in May 2026 and quickly completed its seed round of tens of millions of RMB. The company was founded by internationally renowned top experts in silicon photonics and optical interconnects. Xinguang focuses on the innovative R&D and commercialization of frontier optical interconnect and silicon photonics communication technologies, dedicated to providing core optical interconnect products and next-generation full-stack optical interconnect solutions for global AI computing clusters, with the goal of becoming the defining force in optical interconnect technology for AI computing clusters worldwide. The company follows a three-stage technology roadmap of "NPO entry, CPO mainstream, OIO layout," building full-chain self-developed capabilities spanning chip design, packaging and coupling, to system-level signal integrity. The core R&D team covers silicon photonics chip design, advanced packaging, and high-frequency signal integrity, with each segment leader possessing over 15 years of industry experience, including work experience at leading domestic enterprises and a track record of successful project delivery. Xinguang's first NPO optical engine has initiated technical scheme alignment and validation with leading domestic GPU manufacturers and data center customers, and the company is actively participating in the formulation of core industry standards including ODCC and CPX MSA.

Dong Po, Founder and CEO of Xinguang, stated: "The rapid development of the AI computing industry is driving continuous upgrades in optical interconnect technology demand. Highly integrated, high-performance optical interconnect solutions have become critical support for computing cluster iteration. This RMB 100 million angel funding round represents full recognition of our team's technical accumulation and the development prospects of this track. Going forward, we will continue to deepen our expertise in core optical interconnect technologies, accelerate product iteration and commercialization, refine more competitive industry solutions, and contribute to the innovative development of the computing power optical interconnect industry."

Alex Zhou, Managing Partner of Qiming Venture Partners, stated: "As large-scale AI computing clusters accelerate deployment, highly integrated, high-performance high-speed optical interconnect technology has become a core essential need for the computing power industry upgrade, with broad incremental market potential. The Xinguang team possesses solid underlying technical expertise and mature engineering and commercialization capabilities, with significant advantages in technology self-development, product mass production, and customer deployment. We are very optimistic about the company's development potential in the AI computing power optical interconnect track, and look forward to the company continuing to deepen its technology, refine benchmark products, and continuously empower the innovative development of the computing power optical interconnect industry."

Past Highlights

Qiming Headlines | WAIC Qiming Venture Partners · Entrepreneurship and Investment Forum — The Evolution Journey from Computing Origin to Application Landing Successfully Held

Qiming Stars | Looking Back! Those Exhibitions and Speeches from WAIC 2026 You Couldn't Get Enough Of

Qiming Honors | 5 Qiming Venture Partners Investors Named to 2025 Forbes China Midas List

Qiming Venture Partners was founded in 2006. Currently, the firm manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.

Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hope Medicine, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.